begin view attain rais tp
result help shift deliveri debat toward greater
confid growth target dont expect beat
rais result deliveri growth chang mani mind
overnight question bax abil reach full-year growth
target bax perform help reduc uncertainti issu
creat interest among investor addit reach growth
deliv valu driver includ pipelin inject
pump renal continu margin improv reiter
outperform rate rais target
track reach deliveri growth
equat compound-annual-growth-rate deliveri target
less daunt context compound-annual-growth-rate eas prior year
comparison context deliveri routin deliv mid-
singl growth better past
investor sentiment feedback suggest increment
buyer recent investor sentiment survey suggest sentiment
toward improv feedback convers investor
indic mani investor still convinc suggest us
unlik wide held med-tech name increment
buyer stock investor becom confid management
valuat target price base multipl
ntm ebitda bil bil
target multipl in-lin stock current multipl risk product
delay failur reach lt goal litig regulatory/qu issu
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
inc global manufactur provid
diversifi healthcar suppli equip area renal
hospit product
price jul rate outperform target price analyst matt miksic
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
one-year valuat scenario base
ev/ebitda ebitda bil
scenario base high-growth segment grow
growth grow
one-year valuat grey scenario base
ev/ebitda grey ebitda bil
grey scenario base high-growth segment grow
growth grow
 close
addit detail takeaway
renal mil mil y/i cc organ vs
perform quarter led hsd growth pd therapi ww off-set bax
exit in-cent hd bloodlin busi neg impact sale
mil perform also impact recal certain manufactur
challeng hemodialysi creat temporari suppli constraint howev
compani expect return healthier inventori level next month
expect incur increment cost product capabl facil
enhanc compani expect renal grow cc organ
strong pd growth partial off-set lower sale in-cent hd due compani
strateg exit bloodlin busi expect neg impact renal
sale mil
acut therapi mil mil y/i cc organ vs
acut therapi growth driven continu renal replac therapi crrt
plan expand addit market growth normal
difficult year-over-year comparison compani benefit flu
season mil benefit due flu-rel sale compani expect
acut therapi grow cc organ basi driven new product launch
demand crrt
deliveri mil mil y/i cc organ vs
growth cc quarter repres return balanc growth
ww perform driven strength infus system follow
launch spectrum iq pump north america evo iq pump ou ou growth
driven larg volum iv solut latin america continu momentum
mini-bag compani expect medic deliveri grow cc
organ expect sequenti improv throughout year
growth driven demand hospit pharmaci compound servic genet
inject includ bax metabot anesthesia product partial off-set declin
mil lower sale brevibloc cyclo sale
also impact lower sale anesthesia critic product
compani expect pharmaceut increas lsd cc cyclo sale mil
vs previou guidanc mil ex-cyclo growth expect msd organ
note brevibloc sale organ expect declin mil
clinic nutrit mil mil y/i cc organ
manag expect sale ramp throughout compani work rebuild
 busi capit new product launch compani expect
clinic nutrit grow cc organ
advanc surgeri mil mil y/i cc
compani benefit competit suppli constraint result increment
demand floseal recothrom contribut growth
compani expect advanc surgeri grow hsd cc organ basi
mil mil y/i cc organ vs cse
perform impact tough prior year comp contract manufactur servic
compani expect declin lsd msd cc
 op margin bp estim bp y/i
sale net cog roughli in-lin rel estim lift lower
non-op incom tax partial off-set sg drive upsid
ep gross margin bp estim bp y/i
benefit manufactur improv portfolio initi off-set
lower sale brevibloc cyclo less favor product mix addit
gm also impact increment expens relat enhanc manufactur
capabl bax dialyz facil
compani rais organ sale growth guidanc cc
guidanc cc manag also increas ep guidanc
compani guid cc organ growth ep
sale
sale
ep
estimate
sale
sale
estimate
chang model
increas sale estim ep estim
made rel minor adjust top-lin project
beyond increas sale estim per year averag make minor
adjust year ep estim
figur chang model
charl martineau univers toronto compani mention price
